InspireMD (NSPR) Fundamentals 2026 — Revenue Analysis | SniperIQ
InspireMD (NSPR) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
InspireMD (NSPR) has a market capitalization of approximately
InspireMD's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
InspireMD runs a net profit margin of -344.1%, a gross margin of 28.1%, and an operating margin of -480.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
InspireMD reported revenue of $9M for fiscal year 2025, with net income of -$49M and earnings per share (EPS) of -0.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
InspireMD does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
InspireMD carries a debt-to-equity ratio of 0.07x and a current ratio of 5.15x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For InspireMD (NSPR) the key facts are: market cap
Get InspireMD's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.